Asia Pacific Coagulation Market Forecast to 2030
Asia Pacific Coagulation Market Forecast to 2030 – Regional Analysis – by Disease Indications (Vitamin K Deficiency, Liver Disease, Disseminated Intravascular Coagulation & Pulmonary Embolism, Development of Circulating Anticoagulants, Hemophilia, Von Willebrand’s Disease, and Others), Type [Clinical Laboratory Analyzers (Controls & Calibrators, Assays & Reagents, Instruments/Systems, Coagulation Factors, and Others) and Point-of-Care Testing Analyzers], Offering [Diagnosis (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimmer Testing, Platelets Function Testing, and Others) and Treatment (Anti-Fibrinolytic Drugs, Birth Control Pills, Desmopressin & Immunosuppressive Medicines, Vitamin K Supplements, Blood Thinners, Thrombin Inhibitors or Thrombolytics, Replacement Therapy, Catheter-Assisted Thrombus Removal, and Others)], Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Others), and End User (Clinical Laboratories, Hospitals, and Others)
$2,840 – $4,440
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Growing Organic and Inorganic Strategies by Key Market Players Fuel Asia Pacific Coagulation Market
Changing lifestyle habits and a growing geriatric population are among the major factors increasing the prevalence of blood disorders. Therefore, there is a growing demand for early diagnosis and treatment. Key players are taking several initiatives through various organic and inorganic strategies to enhance the quality of life of patient population.
– In July 2020, Sysmex Corporation launched the Automated Blood Coagulation Analyzers CN-6500/CN-3500 in Japan. The analyzer measures blood coagulation and platelet aggregation parameters, as well as thrombosis and hemostasis parameters.
– In October 2021, Trivitron Healthcare launched a new line of coagulation analyzer products manufactured by Diagon Ltd in India.
– In June 2021, Trivitron Healthcare introduced NANO H5 and NANO H110, which help in monitoring diabetes, hemoglobin variations, and thalassemia.
– In February 2021, Siemens Healthineers and Sysmex Corporation renewed their agreement to supply, distribute, sell, and service hemostasis products across the world. The agreement also included an extension for multiple years. Further, Siemens Healthineers agreed to distribute Sysmex’s automated blood coagulation analyzer, such as the CN-3000 and CN-6000.
– In July 2022, HORIBA Medical launched the latest Yumizen G800 and G1550 hemostasis analyzers, as well as a range of convenient ready-to-use reagents for common blood coagulation Offerings. With this expansion of its product line, HORIBA Medical now offers a comprehensive selection of hemostasis systems and advanced reagents for laboratories of all sizes and requirements.
Thus, the adoption of various organic and inorganic strategies by the key market players is expected to provide opportunities for the coagulation market growth during the forecast period.
Asia Pacific Coagulation Market Overview
The Asia Pacific coagulation market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The factors contributing to the market progress in this region include the rising geriatric population, increasing incidences of cardiovascular diseases, growing prevalence of bleeding disorders, development of distribution networks, and advancements in coagulation analyzers.
According to an article published in the National Center for Biotechnology Information (NCBI), “Cardiovascular Health and Diseases in China 2022,” cardiovascular diseases (CVD) are the cause of ~47% and ~44% of all deaths in rural and urban regions in China, respectively. In 2020, nearly 330 million patients are predicted to suffer from CVD in China. According to a research study published in The Lancet, CVDs cause ~4 million deaths each year in China. CVD patients have elevated levels of coagulation factors in their bodies. Hence, an upsurge in the prevalence of CVDs is fueling the growth of the coagulation market in China.
Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Coagulation Market Segmentation
The Asia Pacific coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.
Based on disease indication, the Asia Pacific coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand’s disease, and others. The liver disease segment held the largest Asia Pacific coagulation market share in 2022.
Based on type, the Asia Pacific coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Asia Pacific coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.
In terms of offering, the Asia Pacific coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Asia Pacific coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.
By technology, the Asia Pacific coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Asia Pacific coagulation market share in 2022.
By end user, the Asia Pacific coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Asia Pacific coagulation market share in 2022.
Based on country, the Asia Pacific coagulation market is categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific coagulation market in 2022.
F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San & Tic Ltd.Şti., Siemens Healthineers AG; Sysmex Corp; and Transasia Bio-Medicals Ltd are some of the leading companies operating in the Asia Pacific coagulation market.
Summary Info
Industry: | |
---|---|
Pricing options: | |
Geographical coverage: | |
Year of Publication: |
According to the Research Team’ research, the Asia Pacific coagulation market was valued at US$ 889.52 million in 2022 and is expected to reach US$ 1,672.49 million by 2030, registering a CAGR of 8.2% from 2022 to 2030. Rising prevalence of cardiovascular diseases and increasing prevalence of blood disorders are among the critical factors attributed to the Asia Pacific coagulation market expansion.
Heart disease is one of the leading causes of hospitalization, death, and reduced physical performance due to conditions such as atrial fibrillation and stroke. It affects the hemostatic system, vascular system, and fluid dynamics of blood and causes arterial and venous thrombosis. Thrombosis is the leading cause of death and complications from cardiovascular disease. Blood vessels damaged by smoking and high blood pressure form cholesterol-rich plaques lining the blood vessels, which can rupture and cause platelets to clot. With coagulation disorders, there is a risk of myocardial infarction, stroke, and atherothrombotic events in the vascular beds. Heart failure (HF) is related to an increased risk of thromboembolism independent of the presence of atrial fibrillation (AF). Platelet activation and coagulation system abnormalities can increase the risk of serious thromboembolic events in patients suffering from HF.
As per ‘Global Burden of Disease Study 2019,’ CVDs were the leading cause of deaths in Asia Pacific in 2019, causing 10.8 million or 35% of the total fatalities.
A coagulation test helps prevent potential heart attack-causing blood clotting. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information on blood clotting status. Thus, the growing incidence of cardiovascular diseases bolsters the coagulation market growth.
On the contrary, high costs associated with coagulation analyzers hampers the growth Asia Pacific coagulation market.
Based on disease indication, the Asia Pacific coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand’s disease, and others. The liver disease segment held 53.9% share of the Asia Pacific coagulation market in 2022, amassing US$ 479.79 million. It is projected to garner US$ 890.13 million by 2030 to expand at 8.0% CAGR during 2022-2030.
Based on type, the Asia Pacific coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held 66.0% share of the Asia Pacific coagulation market in 2022, amassing US$ 586.79 million. It is projected to garner US$ 1,055.37 million by 2030 to expand at 7.6% CAGR during 2022-2030. Clinical laboratory analysers is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.
In terms of offering, the Asia Pacific coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held 64.8% share of the Asia Pacific coagulation market in 2022, amassing US$ 576.59 million. It is projected to garner US$ 1,070.80 million by 2030 to expand at 8.0% CAGR during 2022-2030. Diagnosis is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.
By technology, the Asia Pacific coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held 61.0% share of Asia Pacific coagulation market in 2022, amassing US$ 542.48 million. It is projected to garner US$ 1,029.88 million by 2030 to expand at 8.3% CAGR during 2022-2030.
By end user, the Asia Pacific coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held 60.4% share of Asia Pacific coagulation market in 2022, amassing US$ 537.04 million. It is projected to garner US$ 1,024.27 million by 2030 to expand at 8.4% CAGR during 2022-2030.
Based on country, the Asia Pacific coagulation market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 30.4% share of Asia Pacific coagulation market in 2022, amassing US$ 270.80 million. It is projected to garner US$ 517.62 million by 2030 to expand at 8.4% CAGR during 2022-2030.
Key players operating in the Asia Pacific coagulation market are F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd; Horiba Ltd; ImproGen Diagnostik Kimya San & Tic Ltd.Şti.; Siemens Healthineers AG; Sysmex Corp; and Transasia Bio-Medicals Ltd, among others.
In Feb 2021, Siemens Healthineers and Sysmex Extend Hemostasis Agreement. Siemens Healthineers and Sysmex Corporation announced the renewal of the companies’ long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products including a multi-year extension. As part of the agreement Siemens Healthineers will distribute the new Sysmex CN Systems.
In Aug 2021, Siemens Healthineers Launched Sysmex CN-3000 and CN-6000 Hemostasis Systems. This fully automated CN-3000 and CN-6000 Systems bring mid- and high-volume coagulation testing to laboratories.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific coagulation market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the coagulation market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Coagulation Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Increasing Prevalence of Blood Disorders
4.1.2 Rising Prevalence of Cardiovascular Diseases
4.2 Market Restraints
4.2.1 High Costs Associated with Coagulation Analyzers
4.3 Market Opportunities
4.3.1 Growing Organic and Inorganic Strategies by Key Market Players
4.4 Future Trends
4.4.1 Development of Point-of-Care (POC) Coagulation Analyzers
4.5 Impact Analysis
5. Coagulation Market – Asia Pacific Market Analysis
5.1 Asia Pacific Coagulation Market Revenue (US$ million), 2022 – 2030
6. Asia Pacific Coagulation Market – Revenue and Forecast to 2030 – by Disease Indication
6.1 Overview
6.2 Asia Pacific Coagulation Market Revenue Share, by Disease Indication 2022 & 2030 (%)
6.3 Vitamin K Deficiency
6.3.1 Overview
6.3.2 Vitamin K Deficiency: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Liver Disease
6.4.1 Overview
6.4.2 Liver Disease: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Disseminated Intravascular Coagulation and Pulmonary Embolism
6.5.1 Overview
6.5.2 Disseminated Intravascular Coagulation and Pulmonary Embolism: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Development of Circulating Anticoagulant
6.6.1 Overview
6.6.2 Development of Circulating Anticoagulant: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.7 Hemophilia
6.7.1 Overview
6.7.2 Hemophilia: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.8 Von Willebrand’s Disease
6.8.1 Overview
6.8.2 Von Willebrand’s Disease: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.9 Others
6.9.1 Overview
6.9.2 Others: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Coagulation Market – Revenue and Forecast to 2030 – by Type
7.1 Overview
7.2 Asia Pacific Coagulation Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Clinical Laboratory Analyzers
7.3.1 Overview
7.3.2 Clinical Laboratory Analyzers: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.1 Asia Pacific Coagulation Market, by Clinical Laboratory Analyzers
7.4 Point-of-Care Testing Analyzers
7.4.1 Overview
7.4.2 Point-of-Care Testing Analyzers: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Coagulation Market – Revenue and Forecast to 2030 – by Offering
8.1 Overview
8.2 Asia Pacific Coagulation Market Revenue Share, by Offering 2022 & 2030 (%)
8.3 Diagnosis
8.3.1 Overview
8.3.2 Diagnosis: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 Asia Pacific Coagulation Market, by Diagnosis
8.4 Treatment
8.4.1 Overview
8.4.2 Treatment: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
8.4.2.1 Asia Pacific Coagulation Market, by Treatment
9. Asia Pacific Coagulation Market – Revenue and Forecast to 2030 – by Technology
9.1 Overview
9.2 Asia Pacific Coagulation Market Revenue Share, by Technology 2022 & 2030 (%)
9.3 Optical Technology
9.3.1 Overview
9.3.2 Optical Technology: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Mechanical Technology
9.4.1 Overview
9.4.2 Mechanical Technology: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Electrochemical Technology
9.5.1 Overview
9.5.2 Electrochemical Technology: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Coagulation Market – Revenue and Forecast to 2030 – by End User
10.1 Overview
10.2 Asia Pacific Coagulation Market Revenue Share, by End User 2022 & 2030 (%)
10.3 Clinical Laboratories
10.3.1 Overview
10.3.2 Clinical Laboratories: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Hospitals
10.4.1 Overview
10.4.2 Hospitals: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
11. Asia Pacific Coagulation Market – Country Analysis
11.1 Asia Pacific Coagulation Market, Revenue and Forecast to 2030
11.1.1 Asia Pacific Coagulation Market by Country
11.1.1.1 China
11.1.1.1.1 China Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.1.2 China Coagulation Market, by Disease Indication
11.1.1.1.3 China Coagulation Market, by Type
11.1.1.1.3.1 China Coagulation Market, by Clinical Laboratory Analyzer
11.1.1.1.4 China Coagulation Market, by Offering
11.1.1.1.4.1 China Coagulation Market, by Diagnosis
11.1.1.1.4.2 China Coagulation Market, by Treatment
11.1.1.1.5 China Coagulation Market, by Technology
11.1.1.1.6 China Coagulation Market, by End User
11.1.1.2 Japan
11.1.1.2.1 Overview
11.1.1.2.2 Japan Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.2.3 Japan Coagulation Market, by Disease Indication
11.1.1.2.4 Japan Coagulation Market, by Type
11.1.1.2.4.1 Japan Coagulation Market, by Clinical Laboratory Analyzer
11.1.1.2.5 Japan Coagulation Market, by Offering
11.1.1.2.5.1 Japan Coagulation Market, by Diagnosis
11.1.1.2.5.2 Japan Coagulation Market, by Treatment
11.1.1.2.6 Japan Coagulation Market, by Technology
11.1.1.2.7 Japan Coagulation Market, by End User
11.1.1.3 India
11.1.1.3.1 Overview
11.1.1.3.2 India Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.3.3 India Coagulation Market, by Disease Indication
11.1.1.3.4 India Coagulation Market, by Type
11.1.1.3.4.1 India Coagulation Market, by Clinical Laboratory Analyzer
11.1.1.3.5 India Coagulation Market, by Offering
11.1.1.3.5.1 India Coagulation Market, by Diagnosis
11.1.1.3.5.2 India Coagulation Market, by Treatment
11.1.1.3.6 India Coagulation Market, by Technology
11.1.1.3.7 India Coagulation Market, by End User
11.1.1.4 Australia
11.1.1.4.1 Overview
11.1.1.4.2 Australia Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.4.3 Australia Coagulation Market, by Disease Indication
11.1.1.4.4 Australia Coagulation Market, by Type
11.1.1.4.4.1 Australia Coagulation Market, by Clinical Laboratory Analyzer
11.1.1.4.5 Australia Coagulation Market, by Offering
11.1.1.4.5.1 Australia Coagulation Market, by Diagnosis
11.1.1.4.5.2 Australia Coagulation Market, by Treatment
11.1.1.4.6 Australia Coagulation Market, by Technology
11.1.1.4.7 Australia Coagulation Market, by End User
11.1.1.5 South Korea
11.1.1.5.1 Overview
11.1.1.5.2 South Korea Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.5.3 South Korea Coagulation Market, by Disease Indication
11.1.1.5.4 South Korea Coagulation Market, by Type
11.1.1.5.4.1 South Korea Coagulation Market, by Clinical Laboratory Analyzer
11.1.1.5.5 South Korea Coagulation Market, by Offering
11.1.1.5.5.1 South Korea Coagulation Market, by Diagnosis
11.1.1.5.5.2 South Korea Coagulation Market, by Treatment
11.1.1.5.6 South Korea Coagulation Market, by Technology
11.1.1.5.7 South Korea Coagulation Market, by End User
11.1.1.6 Rest of Asia Pacific
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.6.3 Rest of Asia Pacific Coagulation Market, by Disease Indication
11.1.1.6.4 Rest of Asia Pacific Coagulation Market, by Type
11.1.1.6.4.1 Rest of Asia Pacific Coagulation Market, by Clinical Laboratory Analyzer
11.1.1.6.5 Rest of Asia Pacific Coagulation Market, by Offering
11.1.1.6.5.1 Rest of Asia Pacific Coagulation Market, by Diagnosis
11.1.1.6.5.2 Rest of Asia Pacific Coagulation Market, by Treatment
11.1.1.6.6 Rest of Asia Pacific Coagulation Market, by Technology
11.1.1.6.7 Rest of Asia Pacific Coagulation Market, by End User
12. Coagulation Market-Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Coagulation Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Siemens Healthineers AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Sysmex Corp
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Genrui Biotech Co., Ltd.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Transasia Bio-Medicals Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Horiba Ltd.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Coagulation Market Segmentation
Table 2. Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzers
Table 3. Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 4. Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 5. Optical Technologies and Their Applications
Table 6. Mechanical Technologies and Their Applications
Table 7. China Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 8. China Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 9. China Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzer
Table 10. China Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 11. China Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 12. China Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 13. China Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 14. China Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 15. Japan Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 16. Japan Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 17. Japan Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzer
Table 18. Japan Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 19. Japan Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 20. Japan Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 21. Japan Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 22. Japan Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 23. India Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 24. India Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 25. India Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzer
Table 26. India Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 27. India Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 28. India Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 29. India Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 30. India Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 31. Australia Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 32. Australia Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 33. Australia Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzer
Table 34. Australia Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 35. Australia Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 36. Australia Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 37. Australia Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 38. Australia Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 39. South Korea Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 40. South Korea Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 41. South Korea Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzer
Table 42. South Korea Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 43. South Korea Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 44. South Korea Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 45. South Korea Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 46. South Korea Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 47. Rest of Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 48. Rest of Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 49. Rest of Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzer
Table 50. Rest of Asia Pacific Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 51. Rest of Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 52. Rest of Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 53. Rest of Asia Pacific Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 54. Rest of Asia Pacific Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 55. Recent Inorganic Growth Strategies in the Coagulation Market
Table 56. Recent Organic Growth Strategies in the Coagulation Market
Table 57. Glossary of Terms, Coagulation Market
LIST OF FIGURES
Figure 1. Asia Pacific Coagulation Market Segmentation, By Country
Figure 2. Asia Pacific Coagulation Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Coagulation Market Revenue (US$ million), 2020 – 2030
Figure 5. Asia Pacific Coagulation Market Revenue Share, by Disease Indication 2022 & 2030 (%)
Figure 6. Vitamin K Deficiency: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Liver Disease: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Disseminated Intravascular Coagulation and Pulmonary Embolism: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Development of Circulating Anticoagulant: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Hemophilia: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Von Willebrand’s Disease: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Others: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Asia Pacific Coagulation Market Revenue Share, by Type 2022 & 2030 (%)
Figure 14. Clinical Laboratory Analyzers: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Point-of-Care Testing Analyzers: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Asia Pacific Coagulation Market Revenue Share, by Offering 2022 & 2030 (%)
Figure 17. Diagnosis: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Treatment: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Coagulation Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 20. Optical Technology: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Mechanical Technology: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Electrochemical Technology: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Others: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Asia Pacific Coagulation Market Revenue Share, by End User 2022 & 2030 (%)
Figure 25. Clinical Laboratories: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Hospitals: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Others: Asia Pacific Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Coagulation Market, By Geography, 2022 (US$ Million)
Figure 29. Asia Pacific Coagulation Market, By Key Countries, 2022 and 2030 (%)
Figure 30. China Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 31. Japan Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 32. India Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 33. Australia Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 34. South Korea Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 35. Rest of Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 36. Growth Strategies in the Coagulation Market
The List of Companies – Asia Pacific Coagulation Market
1. F. Hoffmann-La Roche Ltd
2. Genrui Biotech Co Ltd
3. Horiba Ltd.
4. ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti.
5. Siemens Healthineers AG
6. Sysmex Corp
7. Transasia Bio-Medicals Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.